DUBLIN–(BUSINESS WIRE)–The “Birch
Pollen Allergy – Pipeline Review, H1 2019” drug pipelines has
been added to ResearchAndMarkets.com’s offering.
Birch Pollen Allergy – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Birch Pollen Allergy (Immunology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key
players involved in therapeutic development for Birch Pollen Allergy and
features dormant and discontinued projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Preclinical and Discovery stages are 2,
2, 3 and 2 respectively.
Birch Pollen Allergy (Immunology) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic
landscape of Birch Pollen Allergy (Immunology).
The pipeline guide reviews pipeline therapeutics for Birch Pollen
Allergy (Immunology) by companies and universities/research institutes
based on information derived from company and industry-specific
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
The pipeline guide reviews key companies involved in Birch Pollen
Allergy (Immunology) therapeutics and enlists all their major and
The pipeline guide evaluates Birch Pollen Allergy (Immunology)
therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued
The pipeline guide reviews latest news related to pipeline
therapeutics for Birch Pollen Allergy (Immunology)
Reasons to Buy
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under
development for Birch Pollen Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding
Birch Pollen Allergy (Immunology) pipeline depth and focus of
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Featured News & Press Releases
Dec 13, 2018: Anergis reports positive preclinical proof-of concept
data of the Second-Generation COP Allergy Vaccine
Sep 05, 2018: Anergis initiates development of second-generation COP
Allergy Vaccines; announces publication of sustained efficacy data
from Ph. IIb study follow-Up
Aug 14, 2018: HAL Allergy first company to achieve marketing
authorisations in line with Therapieallergene-Verordnung (TAV) in
May 27, 2018: Allergy experts: Clinical effect of ALK’s tree
SLIT-tablet among the most significant ever seen in allergy
- Jun 14, 2017: Desentum has two presentations in EAACI 2017
May 10, 2017: Desentum is preparing to start clinical trials with
birch pollen allergy vaccine
Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited
in Pivotal Phase III Birch Immunotherapy B301 Study
May 17, 2016: HAL Allergy has successfully completed its Phase III
short-term efficacy trial with its sublingual allergen immunotherapy
(SLIT) liquid product for the treatment of birch pollen allergy
May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results
From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic
Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose
ranging study in Germany and Austria
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study
Results in an Approved, Accelerated up-dosing Regimen
- May 12, 2013: Desentum: EARTO innovation prize to VTT
Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomays
Bet v 1
- ALK-Abello AS
- Allergy Therapeutics PLC
- Anergis S.A.
- Biomay AG
- Desentum Oy
- HAL Allergy B.V.
- Laboratorios LETI S.L.
- S-TARget therapeutics GmbH
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s5z8rs
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900